Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Idiopathic Pulmonary Fibrosis: Update Bulletin [December 2015]

Product Code:
Publication Date:
December 2015

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF): Topics covered include opinions about the potential of Promedior’s PRM-151 and Galapagos’ GLPG1690; real world data presented for Roche’s Esbriet (pirfenidone), as well as findings from the IPF-PRO Registry, an academic-industry alliance between Boehringer Ingelheim and the Duke Clinical Research Institute.

Key Questions Answered in this Update Bulletin:

  • How optimistic are KOLs about the potential of Promedior’s anti-fibrotic immunomodulator, PRM-151, as a treatment for IPF?
  • How much potential do KOLs believe PRM-151has for use in combination with other agents?
  • How do KOLs view the potential of Galapagos’ autotaxin inhibitor, GLPG1690, as a future treatment for IPF?
  • What impact does the real world data presented for Roche’s Esbriet (pirfenidone) at the ERS 2015 Annual Congress have on KOL perception of this agent?
  • What do KOLs think about the initial results released from the IPF-PRO Registry?
  • Do KOLs perceive a need for improved methods for diagnosing IPF?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved